Evoke Pharma, a biotech focused on the development of drugs to treat gastrointestinal disorders and diseases, filed on Friday with the SEC to raise up to $23 million in an initial public offering. The San Diego, CA-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol EVOK. The company is yet to generate revenue. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
